Monthly Archives: January 2012

ATCC SDO Releases Ground-Breaking Standard for Human Cell Lines

Posted: Published on January 31st, 2012

MANASSAS, Va.--(BUSINESS WIRE)-- The ATCC® Standards Development Organization (ATCC SDO), an entity of ATCC, has published its second voluntary consensus standard, ASN-0002: “Authentication of Human Cell Lines: Standardization of STR Profiling.” This consensus standard is expected to have broad impact across basic cell research, drug discovery, and translational medicine. This approved American National Standard represents a major step forward in correcting the long standing problem of cell line misidentification. The standard’s intent is to delineate a standardized, universally applicable method for authenticating new and established human cell lines and human primary tissue used in research. A living document, the standard will be subject to revisions over time to reflect changes in the field and new methodologies. “This new standard is one example of our commitment to the program mission for the ATCC SDO---to develop and publish stakeholder-proposed, industry-relevant standards for biomaterials and related processes,” said Raymond Cypess, DVM, PhD, Chief Executive Officer for ATCC. “We are creating and maintaining biological standards that protect public interests,” said Dr. Cypess, “and we endeavor to ensure that government, regulatory agencies, industry and academia have the tools and resources to ensure the importance of properly authenticated material for biological research and product development.” Human cell … Continue reading

Posted in Cell Medicine | Comments Off on ATCC SDO Releases Ground-Breaking Standard for Human Cell Lines

Biomerica Launches New Patented Test to Identify Individuals at Risk of Developing Severe Side Effects From Thiopurine …

Posted: Published on January 31st, 2012

IRVINE, CA--(Marketwire -01/31/12)- Biomerica, Inc. (OTC.BB: BMRA.OB - News) announced that it has launched a new patented Thiopurine methyltransferase (TPMT) test to detect patients who are at risk of developing severe or fatal side effects if treated with the class of thiopurine drugs that includes azathioprine, mercaptopurine, and thioguanine. Thiopurine drugs suppress the immune system and are used in the treatment of a wide range of diseases, such as inflammatory bowel disease, leukemia and lymphoma, autoimmune diseases and skin disorders such as psoriasis and severe eczema. They are also used to treat organ transplant patients. The most commonly used thiopurine drug is called azathioprine. It is estimated that one in every 300 people lacks TPMT, which is an enzyme that helps remove thiopurine drugs from the body when they are present. Individuals who lack the TPMT enzyme can become severely or fatally ill if treated with normal doses of thiopurine drugs because toxic levels of the drug accumulate. "Currently the two main U.S. reference labs offering TMPT testing charge over $200 per sample. We expect that our test will allow any lab or hospital to lower what they charge for TPMT testing to less than $120 per sample, a 40% … Continue reading

Posted in Drug Side Effects | Comments Off on Biomerica Launches New Patented Test to Identify Individuals at Risk of Developing Severe Side Effects From Thiopurine …

Plavix Side Effects Lawsuit Filed in Illinois State Court

Posted: Published on January 31st, 2012

Posted by Shezad Malik MD JDJanuary 30, 2012 9:29 PM A product liability lawsuit has been filed against the manufacturers of the popular cardiac medication Plavix. The complaint filed against Bristol-Myers Squibb and Sanofi Aventis, allege that the manufacturers of Plavix lied about the drug’s safety and effectiveness. The Plavix complaint was filed in St. Clair County Circuit Court in Illinois and alleges that Plavix caused the plaintiffs to suffer injuries, economic losses and medical costs because the companies provided inadequate warnings and falsely claimed that the popular blood thinner was more effective, and safer, than aspirin. Plavix (clopidogrel) is a blood thinner (anti platelet agent) that prevents blood platelets from sticking together to form clots. Plavix Injuries and Side Effects There is a growing number of Plavix lawsuits filed, in which plaintiffs allege that they suffered injuries as a result of their unnecessary use of Plavix, including gastrointestinal bleeding, severe ulcers, heart attacks, strokes and a blood disorder known as TTP, or thrombotic thrombocytopenic purpora. Plavix cited by FDA for off label promotion Plaintiffs claim that the drug makers repeatedly overstated the safety and effectiveness of Plavix. Furthermore, they spotlight that the companies were repeatedly cited by the FDA … Continue reading

Posted in Drug Side Effects | Comments Off on Plavix Side Effects Lawsuit Filed in Illinois State Court

Rooney Mara – Rooney Mara Joins Side Effects

Posted: Published on January 31st, 2012

Rooney Mara will replace Blake Lively in Steven Soderbergh's forthcoming prescription drugs drama 'Side Effects'. Rooney Mara has replaced Blake Lively in Steven Soderbergh's 'Side Effects'. The 26-year-old actress - who recently won an Oscar-nomination for her performance in 'Girl with the Dragon Tattoo' - will now play the leading role of Emily Hawkins in the movie about a woman with a prescription drug addiction, Deadline.com reports. Her problems increase when she is forced to come to terms with her husband being released from prison after three years, and she begins an affair with her doctor. Jude Law, Channing Tatum and Catherine Zeta-Jones are also set to star in the movie, which has been written by Scott Z. Burns. Greg Jacobs and Lorenzo di Bonaventura are producing the film, and shooting begins in April. The role will be Rooney's first major signing since appearing in the English language version of 'Girl with the Dragon Tattoo' alongside Daniel Craig. She was thought to be in line for a role in Kathryn Bigelow's movie about the death of Osama bin Laden, but could not sign on due to promotional work for 'Dragon Tattoo'. Read more: Rooney Mara - Rooney Mara Joins Side … Continue reading

Posted in Drug Side Effects | Comments Off on Rooney Mara – Rooney Mara Joins Side Effects

Rimonabant suppliers – Video

Posted: Published on January 31st, 2012

14-11-2011 14:16 link to online store pillsrx24.com Rimonabant suppliers Acomplia (Rimonabant) is an anti-obesity drug to rival Xenical and Reductil in Europe and Meridia in the US. Acomplia Diet Pills Rimonabant 17 Dec 2007. Car sickness is a form of motion sickness, which some people experience riding in automobiles, airplanes, boats, trains, and amusement rides. My friend Audrey, a Doom aficionado, diagnosed my condition as dims. "Doom-induced motion sickness," she explained. "Lots of people get it. At first.". You will find complete options to buy your Sildenafil Citrate or tadalafil to effectively treat erectile dysfunction (ED). 5 Jan 2010. Drugs are hardly better than a placebo for the mildly depressed, researchers find. rimonabant suppliers rimonabant suppliers india The rest is here: Rimonabant suppliers - Video … Continue reading

Posted in Wholesale Pharmacy | Comments Off on Rimonabant suppliers – Video

'I Wanted To Live': New Depression Drugs Offer Hope For Toughest Cases

Posted: Published on January 31st, 2012

Enlarge Lianne Milton for NPR Chris Stephens, 28, who has been battling depression all of his life, plays with his dogs at home in Concord, Calif., on Friday. After a dose of ketamine, Stephens says, "I actually wanted to do things. I wanted to live life." Lianne Milton for NPR Chris Stephens, 28, who has been battling depression all of his life, plays with his dogs at home in Concord, Calif., on Friday. After a dose of ketamine, Stephens says, "I actually wanted to do things. I wanted to live life." A club drug called "Special K" is generating a lot of buzz among researchers who study depression. That's because "Special K," which is actually an FDA-approved anesthetic named ketamine, can relieve even suicidal depression in a matter of hours. And it works on many patients who haven't responded to current antidepressants like Prozac. Those traditional drugs, which act on the brain's serotonin system, can take more than a month to kick in, and don't work for up to 40 percent of people with major depression. "We can take care of a migraine in hours," says Carlos Zarate, a brain researcher at the National Institute of Mental Health who is … Continue reading

Posted in Drugs | Comments Off on 'I Wanted To Live': New Depression Drugs Offer Hope For Toughest Cases

Earnings Preview: Merck report keys on new drugs

Posted: Published on January 31st, 2012

Drugmaker Merck & Co., the world's third-biggest drugmaker by revenue and a Dow component, will tout recent drug approvals and progress on creating new drugs when it reports its fourth-quarter results before the stock market opens Thursday. WHAT TO WATCH FOR: CEO Kenneth Frazier, at the helm for a year, will discuss development of key experimental drugs among Merck's 20 compounds in late-stage testing. He'll likely note the company, based in Whitehouse Station, N.J., got five products approved last year, including breakthrough hepatitis C drug Victrelis. Frazier likely will discuss progress on his strategy to boost revenue and profit by limiting spending, launching new drugs and increasing sales of existing ones, growing sales in emerging markets and expanding the consumer and animal health businesses. Merck, the maker of Januvia, the top-selling pill for Type 2 diabetes, has been expanding that $3 billion-a-year-plus franchise. Its Janumet pill combines widely used generic metformin with Januvia, which increases insulin production and decreases the liver's glucose production. In October, Merck got approval for Juvisync, the first combination pill for the millions who have both diabetes and high cholesterol. The company is expecting a Food and Drug Administration decision this quarter on whether it can … Continue reading

Posted in Drugs | Comments Off on Earnings Preview: Merck report keys on new drugs

Sytropin HGH – Video

Posted: Published on January 31st, 2012

05-12-2011 08:43 Sytropin HGH - link to online store rxdrughost.com Human Growth Hormone Arguably the most important hormone in the body, Human Growth Hormone, or HGH, is produced by the pituitary gland in the brain. Premium quality of HGH - Human Growth Hormone sytropin hgh spray guide sytropin hgh side... Read more: Sytropin HGH - Video … Continue reading

Posted in Online Pharmacy | Comments Off on Sytropin HGH – Video

Catalyst Pharmaceutical Partners to Present CPP-115 Progress at the 2012 Epilepsy Pipeline Update Conference

Posted: Published on January 31st, 2012

CORAL GABLES, Fla., Jan. 31, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX - News) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief Scientific Officer, will present CPP-115 progress at the 2012 Epilepsy Pipeline Update Conference on Thursday, February 2nd at 11:20 a.m. PST. The conference will be held on February 2nd through February 4th at the Hyatt Regency Hotel in San Francisco, California. Hosted by the Epilepsy Therapy Project, the 2012 Epilepsy Pipeline Update Conference is a showcase of emerging and established central nervous system (CNS) companies presenting their strategies, drug candidates and development programs to potential investors and partners. CPP-115 is Catalyst's next-generation GABA aminotransferase (GABA-AT) inhibitor that is in Phase I(a) development targeting cocaine dependency, infantile spasms and refractory partial complex seizures, along with other potential CNS indications. Catalyst's presentation materials from the conference will be posted on February 2nd at http://www.catalystpharma.com under "Events & Presentations" in the "Investors" section. About Catalyst Pharmaceutical Partners, Inc. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system. Catalyst has two products in development, and is currently evaluating its … Continue reading

Comments Off on Catalyst Pharmaceutical Partners to Present CPP-115 Progress at the 2012 Epilepsy Pipeline Update Conference

Researchers visualize the development of Parkinson's cells

Posted: Published on January 31st, 2012

Public release date: 31-Jan-2012 [ | E-mail | Share ] Contact: Katherine Scott katherine.scott@jove.com 617-765-4367 x301 The Journal of Visualized Experiments In the US alone, at least 500,000 people suffer from Parkinson's disease, a neurological disorder that affects a person's ability to control his or her movement. New technology from the University of Bonn in Germany lets researchers observe the development of the brain cells responsible for the disease. Up until now, research into the brain cells responsible for Parkinson's disease has focused on the function and degeneration of these neurons in the adult and aging brain. The new tissue slicing method, which will be published in the world's only peer-reviewed science video journal, the Journal of Visualized Experiments (JoVE), allows scientists to observe the development of these brain cells for the first time. "Little is known about the behavior of these neurons during their differentiation and migration phase," said article author Dr. Sandra Blaess, "and with this technique, we can really observe how these cells behave during development." The new technique also makes the cells available for genetic manipulation, and more information about how these cells develop and function could lead to new treatment options. "Being able to visualize … Continue reading

Posted in Parkinson's Treatment | Comments Off on Researchers visualize the development of Parkinson's cells